共 90 条
- [1] Sanz MA(2004)Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group Blood 103 1237-1243
- [2] Martín G(1997)All-trans-retinoic acid in acute promyelocytic leukemia N Engl J Med 337 1021-1028
- [3] González M(2001)Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies Leuk Lymphoma 42 1265-1273
- [4] León A(2010)Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data J Clin Oncol 28 3866-3871
- [5] Rayón C(2013)Retinoic acid and arsenic trioxide for acute promyelocytic leukemia N Engl J Med 369 111-121
- [6] Rivas C(2017)Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial J Clin Oncol 35 605-612
- [7] Tallman MS(2015)Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukemia in all risk groups (AML17): results of a randomized, controlled, phase 3 trial Lancet Oncol 16 1295-1305
- [8] Andersen JW(2014)Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system Blood 124 1998-2000
- [9] Schiffer CA(2012)All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) Blood 120 1570-1580
- [10] Appelbaum FR(2015)Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukemia in the Australasian Leukemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial Lancet Haematol 2 357-366